Discover the science behind one of the most exciting and controversial advancements in weight management: GLP-1 receptor agonist medications. In this video, we delve into how these medications aid in weight loss, their mechanism of action, and the potential benefits they offer. We also explore the possible risks and side effects to give you a comprehensive understanding of these treatments.
Dietitians On Demand’s Post
More Relevant Posts
-
Medical Director | Clinical Development | Medical Affairs Leadership | Global & Regional experience in Oncology, Hematology, Neurology, Rare Disease
🌟 Important Update on Medicine Shortages 🌟 🚨 The EMA and HMA are addressing shortages of essential diabetes and weight management drugs like Ozempic, Saxenda, Trulicity, and Victoza. 🚨 🌍💊 Importance of GLP-1 Receptor Agonists: These medicines are crucial for managing diabetes and weight in people with obesity or related health issues. 📈 Why the Shortages? Since 2022, high demand and manufacturing issues have led to shortages, worsened by misuse for cosmetic weight loss and the risk of fake products. 🚫💊 🔍 Here's what they're doing to help: ➡️ Collaborating: Bringing together industry, regulators, healthcare professionals, and the public. ➡️ Controlling Distribution: Working with manufacturers to ensure fair distribution. ➡️ Prioritising Patients: Making sure those who need these medicines the most get them. ➡️ Boosting Production: Increasing manufacturing capacity. ➡️ Educating: Raising awareness about the proper use of these drugs. A big workshop is scheduled for July 1, 2024, to discuss more solutions. ✅ A big workshop is scheduled for July 1, 2024, to discuss more solutions. 🤝 👥 For the public: ➡️ Use these medicines only under medical supervision. ⚠️ ➡️ Avoid buying from unverified online sources. ❌ ➡️ Talk to your doctor if your medicine is unavailable. 💬 🔗 More info: EMA Official Site hashtag #Healthcare hashtag #Pharmaceuticals hashtag #GLP1 hashtag #DiabetesCare hashtag #WeightManagement hashtag #PublicHealth hashtag #MedicineShortages hashtag #PatientCare hashtag #DrugSafety hashtag #MedicalUpdates hashtag #RegulatoryActions hashtag #HealthAwareness hashtag #DiabetesManagement hashtag #WeightLoss hashtag #ObesityTreatment @EMA_News @HMA_Health @DiabetesUK @DiabetesAssoc @HealthEU @ObesitySociety @PharmaNews @Healthline @WHO @UNHealth
We have just published recommendation to help tackle shortages of #GLP1 receptor agonists across the EU 💊🤲 looking out for the patients who need them most. ▶ https://lnkd.in/eW9yvkrN
-
Healthcare is a fascinating area of balancing needs and wants.
We have just published recommendation to help tackle shortages of #GLP1 receptor agonists across the EU 💊🤲 looking out for the patients who need them most. ▶ https://lnkd.in/eW9yvkrN
-
🔑 Unlocking Longevity Potential: Could GLP-1 Receptor Agonists (RA) be the key? https://ow.ly/2QrG50QJJLN Access the full insights article to learn more: https://lnkd.in/ej3ZVWBs
-
-
Editor-in-Chief, Journal of Medicinal Chemistry at American Chemical Society
Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists https://lnkd.in/e9qp4tDc
-
#ArticlesInPress: GLP-1 receptor agonists and vascular protection Brady Park et al. https://ow.ly/XV6I50R499w #atherosclerosis #endothelialdysfunction #oxidative stress
-
-
From #ADASciSessions: New data from the phase 2 MOMENTUM trial suggests pemvidutide, Altimmune, Inc.'s GLP-1/Glucagon receptor agonist, boasts a "class-leading" effect on preservation of lean mass with more than 70% of the mean body weight reduction seen in the trial attributable to a reduction in fat mass. Learn more about the latest presented by Louis Aronne, MD: https://lnkd.in/e63Cjp2i #Obesity
-
-
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study https://lnkd.in/guz9v8wf
-
Professor of Molecular and Cellular Pharmacology, University of Nottingham and Founder, Z7 Biotech Ltd
Happy to share our latest paper explaining the basis for partial agonism at beta2 adrenergic receptor https://lnkd.in/gaNv3SKU
-
-
founder ,and General Manager at Excellency health,and health related consultancy,and training PLC .#safety # quality # researcher# project managements #strategies # grant ship writing # feasibility study
(b) Antagonists Ligands that prevent an agonist from binding to a receptor and thus prevent its effects are called antagonists. Antagonists do not themselves have any pharmacological actions mediated by receptors. For example, propranolol, a β-adrenoceptor antagonist, binds to β-adrenoceptors in the heart and prevents catecholamine-induced tachycardia (for example in response to exercise). However, in the absence of an agonist propranolol has no effect via adrenoceptors.
